ABOLOGIX is one of the winners in Stage I of the Venture Kick competition

Geneva, Switzerland, June 10, 2020 – Abologix will receive funding from Venture Kick in order to advance its business development activities and its fundraising efforts.

One of the top 50 start ups in french-speaking Switzerland

Geneva, Switzerland, December 18, 2019 – Abologix is profiled in the leading swiss Business magazine “Bilan” as one of the most promissing start ups in Suisse Romande. The company has been invited to present its investment case in a future event sponsored by “Bilan” to be held in Lausanne, Switzerland.

ABOLOGIX obtains positive pre-clinical proof-of-concept results with its monoclonal antibody H225

Geneva, Switzerland, July 24, 2019 – Recombinant monoclonal antibody H225, a blocker of JAM-C (Junction Adhesion Molecule C) generates impressive efficacy data in a Mantle Cell Lymphoma animal model.